Metabolic engineering of Escherichia coli for the preparation of C14-enriched monophosphorylated lipid A homologs via an integrated biosynthesis-hydrolysis strategy

Glucopyranosyl lipid adjuvant (GLA) is a potent TLR4 agonist, but access to GLA adjuvants is constrained by complex chemical synthesis. We aimed to establish a biosynthesis-assisted route that combines microbial lipid A pathway engineering with a downstream chemical release step, using naturally derived MPLA as a reference. To minimize structural heterogeneity and direct secondary acylation toward C14, we engineered Escherichia coli by deleting six diversification genes and replacing native lpxL with vplpxL. The resulting C14-enriched LPS precursor was processed using a single mild acid-hydrolysis step, bypassing the conventional alkaline deacylation required for clinical-grade S. minnesota R595-derived MPLA. The purified product, GLA-Cx, was structurally characterized by high-resolution MS/MS and evaluated using complementary structural and impurity-related quality-control readouts (TLC, rFC, and hTLR2); it demonstrated in vitro murine and human TLR4 agonist activity. This process enabled repeatable recovery of 2.0–5.0 g per 35-L batch (57–143 mg L⁻¹), with combined penta- and hexa-acylated fractions of 43.92%–78.06% (61.30 ± 14.69%, mean ± SD, n = 5) of the grouped tetra- to hexa-acylated CAD area, compared with 26.97% for MPLA-SM. We establish an integrated genotype-to-product proof of concept for preparing C14-enriched monophosphorylated lipid A homologs from an engineered microbial cell factory. By combining W3110’s genetic tractability and hexa-acylated lipid A background with C14-directed design, single-step acid release without subsequent alkaline deacylation, and multi-gram recovery, this framework provides a basis for scalable production and quality-control development of complex lipid-based adjuvants.

Authors

Institutions

Publication Details

Journal
Microbial Cell Factories
Published
2026-11-16
DOI
https://doi.org/10.1186/s12934-026-03172-x
Primary Topic
Microbial Metabolic Engineering and Bioproduction
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Metabolic engineering of Escherichia coli for the preparation of C14-enriched monophosphorylated lipid A homologs via an integrated biosynthesis-hydrolysis strategy

Pu Shan, Xin Li, Xu Wang, Jinyan Chen et al.
1 links
Microbial Cell Factories
Microbial Metabolic Engineering and Bioproduction
article

Metabolic engineering of Escherichia coli for the preparation of C14-enriched monophosphorylated lipid A homologs via an integrated biosynthesis-hydrolysis strategy

Pu Shan, Xin Li, Xu Wang, Jinyan Chen, Xinyu Wang, Yue Li, Zhibiao Wang, Shuxiang Li
article en

Abstract

Glucopyranosyl lipid adjuvant (GLA) is a potent TLR4 agonist, but access to GLA adjuvants is constrained by complex chemical synthesis. We aimed to establish a biosynthesis-assisted route that combines microbial lipid A pathway engineering with a downstream chemical release step, using naturally derived MPLA as a reference. To minimize structural heterogeneity and direct secondary acylation toward C14, we engineered Escherichia coli by deleting six diversification genes and replacing native lpxL with vplpxL. The resulting C14-enriched LPS precursor was processed using a single mild acid-hydrolysis step, bypassing the conventional alkaline deacylation required for clinical-grade S. minnesota R595-derived MPLA. The purified product, GLA-Cx, was structurally characterized by high-resolution MS/MS and evaluated using complementary structural and impurity-related quality-control readouts (TLC, rFC, and hTLR2); it demonstrated in vitro murine and human TLR4 agonist activity. This process enabled repeatable recovery of 2.0–5.0 g per 35-L batch (57–143 mg L⁻¹), with combined penta- and hexa-acylated fractions of 43.92%–78.06% (61.30 ± 14.69%, mean ± SD, n = 5) of the grouped tetra- to hexa-acylated CAD area, compared with 26.97% for MPLA-SM. We establish an integrated genotype-to-product proof of concept for preparing C14-enriched monophosphorylated lipid A homologs from an engineered microbial cell factory. By combining W3110’s genetic tractability and hexa-acylated lipid A background with C14-directed design, single-step acid release without subsequent alkaline deacylation, and multi-gram recovery, this framework provides a basis for scalable production and quality-control development of complex lipid-based adjuvants.

Microbial Cell Factories
National Vaccine and Serum Institute (CN)
Good health and well-being
Microbial Metabolic Engineering and Bioproduction
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon